Product Pipeline
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.?
Key Innovative Programs
- Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
- Bavencio? (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
- Braftovi? (encorafinib) + Mektovi? (binimetinib)?: BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
- Duchenne Muscular Dystrophy Gene Therapy
- fidanacogene elaparvovec (Gene Therapy, coagulation factor IX): Hemophilia
- giroctocogene fitelparvovec (Gene Therapy, coagulation factor VIII): Hemophilia
- Ibrance? (palbociclib): High Risk Early Breast Cancer
- Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
- Prophylactic Vaccine: Clostridioides difficile Infection Prophylactic Vaccine: Respiratory Syncytial Virus Infection (maternal)
- Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata
- Talzenna? (talazoparib): Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
- Xeljanz? (tofacitinib): Ankylosing Spondylitis
- Xtandi? (enzalutamide): Metastatic Castration Sensitive Prostate Cancer, Non-Metastatic High Risk Castration Sensitive Prostate Cancer
Pipeline Snapshot as of July 28, 2020
- Discovery Projects
- 25Phase 1
- 38Phase 2
- 23Phase 3
- 4Registration
- Total90
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
PF-06425090 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Primary clostridioides difficile infection (FAST TRACK) | Phase 3 | New Molecular Entity | Vaccine |
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (adult) (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Vaccine |
PF-06482077 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (infants) (FAST TRACK)
Project advanced | Phase 3 | Product Enhancement | Vaccine |
PF-06886992 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Serogroups ABCWY Meningococcal Infections (adolescent and young adults)
Project advanced | Phase 3 | New Molecular Entity | Vaccine |
PF-06928316 Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Respiratory Syncytial Virus Infection (maternal) (FAST TRACK)
Project advanced | Phase 3 | New Molecular Entity | Vaccine |
PF-07302048 (BNT162) Therapeutic Area: Vaccines Phase:Phase 3 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic mRNA Vaccine | COVID-19 Infection (in partnership with BioNTech) (FAST TRACK) (Pivotal Phase 2/3 global study)
Project advanced | Phase 3 | New Molecular Entity | Vaccine |
PF-06760805 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive Group B Streptococcus Infection (maternal) | Phase 2 | New Molecular Entity | Vaccine |
PF-07307405 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Lyme disease
Project advanced | Phase 2 | New Molecular Entity | Vaccine |
PF-06842433 Therapeutic Area: Vaccines Phase:Phase 2 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Prophylactic Vaccine | Invasive and Non-Invasive Pneumococcal infections (infants and children) | Phase 2 | New Molecular Entity | Vaccine |
PF-06881894, a potential biosimilar to Neulasta? (Pegfilgrastim) Therapeutic Area: Oncology Phase:Registration Compound Type:Biosimilar Business Segment: Biopharma Mechanism of Action: Human Granulocyte Colony Stimulating Factor | Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (E.U.) | Registration | Biosimilar | Biosimilar |
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor | Metastatic Castration Sensitive Prostate Cancer (E.U.) | Registration | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Registration Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Urothelial Cancer (Biologic) (E.U.)
Project advanced | Registration | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Daurismo (glasdegib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: SMO (smoothened) antagonist | Combo w/cytarabine and daunorubicin in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) | Phase 3 | Product Enhancement | Small Molecule |
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor | High Risk Early Breast Cancer | Phase 3 | Product Enhancement | Small Molecule |
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor | ER+/HER2+ Breast Cancer | Phase 3 | Product Enhancement | Small Molecule |
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK Inhibitor | 1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) | Phase 3 | Product Enhancement | Small Molecule |
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti-PD-1 | Non-Muscle-Invasive Bladder Cancer (Biologic) | Phase 3 | New Molecular Entity | Biologic |
